Date:\_\_5/1/2024

Your Name:\_\_\_ Chao Sun

Manuscript Title:\_\_\_Improvement of idiopathic pulmonary fibrosis through a combination of Astragalusradix and Angelica sinensisradix via mammalian target of rapamycin signaling pathway-induced autophagy \_\_\_\_\_\_ Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   |  |   |
|   | manuscript (e.g., funding,    | This research was funded   |   |
|   | provision of study materials, | by the National Natural  |   |
|   | medical writing, article      | Science Foundation of  |   |
|   | processing charges, etc.)     | China (No. 82004285).  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | V_None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | _ <u>√</u> None  |   |
|   |                               |  |   |

| 4  | Consulting fees                                   | _√_None         |  |
|----|---|-----------------|--|
|    |   |                 |  |
|    |   |                 |  |
| 5  | Payment or honoraria for                          | None            |  |
|    | lectures, presentations,                          |                 |  |
|    | speakers bureaus,                                 |                 |  |
|    | manuscript writing or<br>educational events       |                 |  |
| 6  | Payment for expert                                | √ None          |  |
| 0  | testimony   |                 |  |
|    |   |                 |  |
| 7  | Support for attending                             | √ None          |  |
|    | meetings and/or travel                            |                 |  |
|    | <b>C</b> .  |                 |  |
|    |   |                 |  |
|    |   |                 |  |
| 8  | Patents planned, issued or                        | _√_None         |  |
|    | pending   |                 |  |
|    |   |                 |  |
| 9  | Participation on a Data                           | _ <u>√</u> None |  |
|    | Safety Monitoring Board or                        |                 |  |
| 10 | Advisory Board                                    |                 |  |
| 10 | Leadership or fiduciary role                      | _√_None         |  |
|    | in other board, society,<br>committee or advocacy |                 |  |
|    | group, paid or unpaid                             |                 |  |
| 11 | Stock or stock options                            | √ None          |  |
|    |   |                 |  |
|    |   |                 |  |
| 12 | Receipt of equipment,                             | _√_None         |  |
|    | materials, drugs, medical                         |                 |  |
|    | writing, gifts or other                           |                 |  |
| 10 | services  |                 |  |
| 13 | Other financial or non-                           | _√_None         |  |
|    | financial interests                               |                 |  |
|    |   |                 |  |

This research was funded by the National Natural Science Foundation of China (No. 82004285).

Please place an "X" next to the following statement to indicate your agreement:

Date:\_\_5/1/2024

Your Name:\_\_\_\_ Huaman Liu

Manuscript Title:\_\_\_Improvement of idiopathic pulmonary fibrosis through a combination of Astragalusradix and Angelica sinensisradix via mammalian target of rapamycin signaling pathway-induced autophagy \_\_\_\_\_\_ Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials, | This research was funded by the National Natural   |   |
|   | medical writing, article<br>processing charges, etc.)                                      | Science Foundation of<br>China (No. 82004285).   |   |
|   | No time limit for this item.   |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated                                   | V_None   |   |
|   | in item #1 above).   |  |   |
| 3 | Royalties or licenses  | <u>√</u> None  |   |
|   |  |  |   |

| 4  | Consulting fees                                   | _√_None         |  |
|----|---|-----------------|--|
|    |   |                 |  |
|    |   |                 |  |
| 5  | Payment or honoraria for                          | None            |  |
|    | lectures, presentations,                          |                 |  |
|    | speakers bureaus,                                 |                 |  |
|    | manuscript writing or<br>educational events       |                 |  |
| 6  | Payment for expert                                | √ None          |  |
| 0  | testimony   |                 |  |
|    | testimony   |                 |  |
| 7  | Support for attending                             | _√_None         |  |
| ,  | meetings and/or travel                            |                 |  |
|    |   |                 |  |
|    |   |                 |  |
|    |   |                 |  |
| 8  | Patents planned, issued or                        | _√_None         |  |
|    | pending   |                 |  |
|    |   |                 |  |
| 9  | Participation on a Data                           | _ <u>√</u> None |  |
|    | Safety Monitoring Board or                        |                 |  |
|    | Advisory Board                                    |                 |  |
| 10 | Leadership or fiduciary role                      | _√_None         |  |
|    | in other board, society,<br>committee or advocacy |                 |  |
|    | group, paid or unpaid                             |                 |  |
| 11 | Stock or stock options                            | √ None          |  |
|    |   |                 |  |
|    |   |                 |  |
| 12 | Receipt of equipment,                             | _√_None         |  |
|    | materials, drugs, medical                         | _               |  |
|    | writing, gifts or other                           |                 |  |
|    | services  |                 |  |
| 13 | Other financial or non-                           | _ <u>√</u> None |  |
|    | financial interests                               |                 |  |
|    |   |                 |  |

This research was funded by the National Natural Science Foundation of China (No. 82004285).

Please place an "X" next to the following statement to indicate your agreement:

Date:\_\_<u>5/1/2024</u>

Your Name:\_\_\_\_ Jia Han

Manuscript Title:\_\_\_Improvement of idiopathic pulmonary fibrosis through a combination of Astragalusradix and Angelica sinensisradix via mammalian target of rapamycin signaling pathway-induced autophagy \_\_\_\_\_\_ Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   |  |   |
|   | manuscript (e.g., funding,    | This research was funded   |   |
|   | provision of study materials, | by the National Natural  |   |
|   | medical writing, article      | Science Foundation of  |   |
|   | processing charges, etc.)     | China (No. 82004285).  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | V_None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | _ <u>√</u> None  |   |
|   |                               |  |   |

| 4  | Consulting fees                                | _√_None         |  |
|----|--|-----------------|--|
|    |  |                 |  |
|    |  |                 |  |
| 5  | Payment or honoraria for                       | None            |  |
|    | lectures, presentations,                       |                 |  |
|    | speakers bureaus,                              |                 |  |
|    | manuscript writing or<br>educational events    |                 |  |
| 6  | Payment for expert                             | √ None          |  |
| 0  | testimony                                      |                 |  |
|    |  |                 |  |
| 7  | Support for attending                          | √ None          |  |
|    | meetings and/or travel                         |                 |  |
|    | <b>C</b> .                                     |                 |  |
|    |  |                 |  |
|    |  |                 |  |
| 8  | Patents planned, issued or                     | _√_None         |  |
|    | pending  |                 |  |
|    |  |                 |  |
| 9  | Participation on a Data                        | _ <u>√</u> None |  |
|    | Safety Monitoring Board or                     |                 |  |
| 10 | Advisory Board                                 |                 |  |
| 10 | Leadership or fiduciary role                   | _√_None         |  |
|    | in other board, society, committee or advocacy |                 |  |
|    | group, paid or unpaid                          |                 |  |
| 11 | Stock or stock options                         | √ None          |  |
|    |  |                 |  |
|    |  |                 |  |
| 12 | Receipt of equipment,                          | _√_None         |  |
|    | materials, drugs, medical                      |                 |  |
|    | writing, gifts or other                        |                 |  |
| 10 | services                                       |                 |  |
| 13 | Other financial or non-                        | _√_None         |  |
|    | financial interests                            |                 |  |
|    |  |                 |  |

This research was funded by the National Natural Science Foundation of China (No. 82004285).

Please place an "X" next to the following statement to indicate your agreement:

Date:\_\_5/1/2024

Your Name: Baihong Chi

Manuscript Title:\_\_\_Improvement of idiopathic pulmonary fibrosis through a combination of Astragalusradix and Angelica sinensisradix via mammalian target of rapamycin signaling pathway-induced autophagy \_\_\_\_\_\_ Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials, | This research was funded by the National Natural   |   |
|   | medical writing, article<br>processing charges, etc.)                                      | Science Foundation of<br>China (No. 82004285).   |   |
|   | No time limit for this item.   |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated                                   | V_None   |   |
|   | in item #1 above).   |  |   |
| 3 | Royalties or licenses  | <u>√</u> None  |   |
|   |  |  |   |

| 4  | Consulting fees                                   | _√_None         |  |
|----|---|-----------------|--|
|    |   |                 |  |
|    |   |                 |  |
| 5  | Payment or honoraria for                          | None            |  |
|    | lectures, presentations,                          |                 |  |
|    | speakers bureaus,                                 |                 |  |
|    | manuscript writing or<br>educational events       |                 |  |
| 6  | Payment for expert                                | √ None          |  |
| 0  | testimony   |                 |  |
|    | testimony   |                 |  |
| 7  | Support for attending                             | _V_None         |  |
| ,  | meetings and/or travel                            |                 |  |
|    |   |                 |  |
|    |   |                 |  |
|    |   |                 |  |
| 8  | Patents planned, issued or                        | _√_None         |  |
|    | pending   |                 |  |
|    |   |                 |  |
| 9  | Participation on a Data                           | _ <u>√</u> None |  |
|    | Safety Monitoring Board or                        |                 |  |
|    | Advisory Board                                    |                 |  |
| 10 | Leadership or fiduciary role                      | _√_None         |  |
|    | in other board, society,<br>committee or advocacy |                 |  |
|    | group, paid or unpaid                             |                 |  |
| 11 | Stock or stock options                            | √ None          |  |
|    |   |                 |  |
|    |   |                 |  |
| 12 | Receipt of equipment,                             | _√_None         |  |
|    | materials, drugs, medical                         | _               |  |
|    | writing, gifts or other                           |                 |  |
|    | services  |                 |  |
| 13 | Other financial or non-                           | _ <u>√</u> None |  |
|    | financial interests                               |                 |  |
|    |   |                 |  |

This research was funded by the National Natural Science Foundation of China (No. 82004285).

Please place an "X" next to the following statement to indicate your agreement:

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | ✓ None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | Nippon Boehringer  |   |
|   | any entity (if not indicated  | Ingelheim  |   |
|   | in item #1 above).            |  |   |
|   |                               |  |   |
| 3 | Royalties or licenses         | ✓ None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | ✓ None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | ✓ None |  |
|----|--|--------|--|
| 6  |  |        |  |
| 6  | Payment for expert testimony   | ✓ None |  |
| 7  | Support for attending meetings and/or travel   | ✓ None |  |
| 8  | Patents planned, issued or pending   | ✓ None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | ✓ None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | ✓ None |  |
| 11 | Stock or stock options   | ✓ None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | ✓ None |  |
| 13 | Other financial or non-<br>financial interests   | ✓ None |  |

Y. Koga received a research grant from Nippon Boehringer Ingelheim Co., Ltd.

# Please place an "X" next to the following statement to indicate your agreement:

Date:\_December 27, 2023\_\_\_\_\_\_ Your Name:\_\_\_Kamyar Afshar, DO\_\_\_\_\_\_ Manuscript Title:\_ Improvement of idiopathic pulmonary fibrosis through a combination of Astragalusradix and Angelica sinensisradix via mammalian target of rapamycin signaling pathway-induced autophagy Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for lectures, presentations,                | XNone  |  |
|----|--|--------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events |        |  |
| 6  | Payment for expert testimony                                     | XNone  |  |
| 7  | Support for attending meetings and/or travel                     | XNone  |  |
|    |  |        |  |
|    |  |        |  |
| 8  | Patents planned, issued or<br>pending                            | XNone  |  |
|    |  |        |  |
| 9  | Participation on a Data  | XNone  |  |
|    | Safety Monitoring Board or<br>Advisory Board                     |        |  |
| 10 | Leadership or fiduciary role                                     | X None |  |
| 10 | in other board, society,   |        |  |
|    | committee or advocacy<br>group, paid or unpaid                   |        |  |
| 11 | Stock or stock options   | XNone  |  |
|    |  |        |  |
|    |  |        |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical               | XNone  |  |
|    | writing, gifts or other<br>services                              |        |  |
| 13 | Other financial or non-  | X None |  |
| 15 | financial interests  |        |  |
|    |  |        |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

Date:\_\_<u>5/1/2024</u>

Your Name: <u>Xue Liu</u>

Manuscript Title:\_\_\_Improvement of idiopathic pulmonary fibrosis through a combination of Astragalusradix and Angelica sinensisradix via mammalian target of rapamycin signaling pathway-induced autophagy \_\_\_\_\_\_ Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |  |  |
|---|--|--|---|--|--|
|   |  | Time frame: Since the initial  | planning of the work  |  |  |
| 1 | All support for the present                              |  |   |  |  |
|   | manuscript (e.g., funding,                               | This research was funded   |   |  |  |
|   | provision of study materials,                            | by the National Natural  |   |  |  |
|   | medical writing, article                                 | Science Foundation of  |   |  |  |
|   | processing charges, etc.)                                | China (No. 82004285).  |   |  |  |
|   | No time limit for this item.                             |  |   |  |  |
|   |  |  |   |  |  |
|   |  |  |   |  |  |
|   |  |  |   |  |  |
|   |  |  |   |  |  |
|   |  |  |   |  |  |
|   | Time frame: past 36 months                               |  |   |  |  |
| 2 | Grants or contracts from<br>any entity (if not indicated | V_None   |   |  |  |
|   |  |  |   |  |  |
|   | in item #1 above).                                       |  |   |  |  |
| 3 | Royalties or licenses                                    | _ <u>√</u> None  |   |  |  |
|   |  |  |   |  |  |

| 4  | Consulting fees   | _√_None |  |
|----|---|---------|--|
|    |   |         |  |
|    |   |         |  |
| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus, | None    |  |
|    |   |         |  |
|    |   |         |  |
|    | manuscript writing or<br>educational events                               |         |  |
| 6  | Payment for expert  | √ None  |  |
| 0  | testimony   |         |  |
|    | testimony   |         |  |
| 7  | Support for attending   | _√_None |  |
| ,  | meetings and/or travel  |         |  |
|    |   |         |  |
|    |   |         |  |
|    |   |         |  |
| 8  | Patents planned, issued or  | _√_None |  |
|    | pending   |         |  |
|    |   |         |  |
| 9  | Participation on a Data   | _√_None |  |
|    | Safety Monitoring Board or  |         |  |
|    | Advisory Board  |         |  |
| 10 | Leadership or fiduciary role  | _√_None |  |
|    | in other board, society,<br>committee or advocacy                         |         |  |
|    | group, paid or unpaid   |         |  |
| 11 | Stock or stock options  | √ None  |  |
|    |   |         |  |
|    |   |         |  |
| 12 | Receipt of equipment,   | _√_None |  |
|    | materials, drugs, medical   | _       |  |
|    | writing, gifts or other services  |         |  |
|    |   |         |  |
| 13 | Other financial or non-<br>financial interests                            | _√_None |  |
|    |   |         |  |
|    |   |         |  |

This research was funded by the National Natural Science Foundation of China (No. 82004285).

Please place an "X" next to the following statement to indicate your agreement: